While Aurora Cannabis Inc has underperformed by -0.85%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ACB fell by -30.85%, with highs and lows ranging from $9.35 to $3.42, whereas the simple moving average fell by -9.24% in the last 200 days.
On December 11, 2024, TD Cowen started tracking Aurora Cannabis Inc (NASDAQ: ACB) recommending Buy. A report published by Canaccord Genuity on February 09, 2024, Upgraded its rating to ‘Buy’ for ACB. Stifel June 06, 2022d its ‘Sell’ rating to ‘Hold’ for ACB, as published in its report on June 06, 2022. Jefferies also rated the stock as ‘Hold’.
Analysis of Aurora Cannabis Inc (ACB)
Further, the quarter-over-quarter increase in sales is 33.35%, showing a positive trend in the upcoming months.
One of the most important indicators of Aurora Cannabis Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of 4.78% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 1.60, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and ACB is recording 2.97M average volume. On a monthly basis, the volatility of the stock is set at 6.69%, whereas on a weekly basis, it is put at 6.51%, with a gain of 8.92% over the past seven days. Furthermore, long-term investors anticipate a median target price of $7.23, showing growth from the present price of $4.64, which can serve as yet another indication of whether ACB is worth investing in or should be passed over.
How Do You Analyze Aurora Cannabis Inc Shares?
The Drug Manufacturers – Specialty & Generic market is dominated by Aurora Cannabis Inc (ACB) based in the Canada. When comparing Aurora Cannabis Inc shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 29.44, there is a growth in quarterly earnings of 208.81%.
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.39%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 9.73% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
ACB shares are owned by institutional investors to the tune of 9.73% at present.
